Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence
Identifieur interne : 001735 ( Istex/Corpus ); précédent : 001734; suivant : 001736Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence
Auteurs : Miriam Rasmussen ; Peter E. Nielsen ; Muthia Manoharan ; Ole Buchardt ; Claus KochSource :
- Journal of Immunological Methods [ 0022-1759 ] ; 1996.
English descriptors
- Teeft :
- Acetic acid, Aluminum hydroxide suspension, Analog, Antibody response, Antiserum, Antiserum pools, Base sequence, Centrifugal evaporator, Conjugate, Detectable antibody response, Different conjugates, Hapten, Hplc, Inhibitory capacity, Microtiter plates, Midpoint, Midpoint position, Monothioate, Monothioate backbone, Nucleic, Nucleic acids, Oligonucleotide, Oligonucleotides, Reaction mixture, Sodium bicarbonate buffer, Strongest response.
Abstract
Abstract: The phosphoromonothioate oligonucleotide HPV (human papilloma virus) sequence (monothioate HPV) 5′-TTG, CTT,CCA,TCT,TCC,TCG,TC-3′ was photocoupled via three different sites (the 5′-end, the 3′-end and the midpoint) to PPD (purified protein derivative) and OA (ovalbumin), and the three types of conjugates (5′-HPV/carrier, 3′-HPV/carrier and midpoint-HPV/carrier) were used for the immunization of mice. Furthermore, a group of mice were immunized with the HPV sequence alone. No detectable antibody response against the monothioate HPV oligonucleotide was seen in mice receiving only the unconjugated monothioate HPV sequence. The OA-coupled monothioate HPV sequence also failed to elicit a detectable antibody response against the monothioate HPV oligonucleotide. However the PPD-conjugated monothioate HPV sequences induced a significant anti-monothioate HPV antibody response in BCG (bacille Calmette Guérin)-primed mice, a result that must be ascribed to the effect of using PPD as a carrier in BCG-primed mice. The antisera from all groups were tested on plates coated with the corresponding OA conjugates. By far the strongest response was obtained in mice receiving the HPV sequence coupled at the midpoint position. Further, all three groups of antisera obtained by immunizing with the different PPD conjugates were tested on microtiter plates coated with one of the three different OA conjugates. The antisera differed in their response depending on which OA conjugate was used for coating of the plate. Again, the midpoint-HPV/PPD antiserum showed the highest response, and this conjugate apparently represents the most efficient immunogen. Results from inhibition experiments with various relevant analogs of the monothioate HPV sequence showed that the three antiserum pools contained antibodies predominantly directed against the conformation of the monothioate backbone structure, but that at least a subpopulation of the antibodies recognized structures, which depended on the specific HPV base sequence.
Url:
DOI: 10.1016/0022-1759(95)00227-8
Links to Exploration step
ISTEX:0B7AD7322BCC0B8F6AAAD87B525D262EF65D4057Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence</title><author><name sortKey="Rasmussen, Miriam" sort="Rasmussen, Miriam" uniqKey="Rasmussen M" first="Miriam" last="Rasmussen">Miriam Rasmussen</name><affiliation><mods:affiliation>Department of Immunology, Statens Seruminstitut, Artillerivej 5, DK-2300 Copenhagen S, Denmark</mods:affiliation></affiliation></author><author><name sortKey="Nielsen, Peter E" sort="Nielsen, Peter E" uniqKey="Nielsen P" first="Peter E." last="Nielsen">Peter E. Nielsen</name><affiliation><mods:affiliation>Department of Biochemistry B, Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark</mods:affiliation></affiliation></author><author><name sortKey="Manoharan, Muthia" sort="Manoharan, Muthia" uniqKey="Manoharan M" first="Muthia" last="Manoharan">Muthia Manoharan</name><affiliation><mods:affiliation>ISIS Pharmaceutical, 2280 Faraday Avenue. Carlsbad, CA 92008, USA</mods:affiliation></affiliation></author><author><name sortKey="Buchardt, Ole" sort="Buchardt, Ole" uniqKey="Buchardt O" first="Ole" last="Buchardt">Ole Buchardt</name><affiliation><mods:affiliation>Department of Organic Chemistry, H.C. Ørsted Institute, University of Copenhagen, Universitetsparken 5, DK-2100 Copenhagen Ø, Denmark</mods:affiliation></affiliation></author><author><name sortKey="Koch, Claus" sort="Koch, Claus" uniqKey="Koch C" first="Claus" last="Koch">Claus Koch</name><affiliation><mods:affiliation>Department of Immunology, Statens Seruminstitut, Artillerivej 5, DK-2300 Copenhagen S, Denmark</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0B7AD7322BCC0B8F6AAAD87B525D262EF65D4057</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1016/0022-1759(95)00227-8</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-57Z5ZPTF-9/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001735</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001735</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence</title><author><name sortKey="Rasmussen, Miriam" sort="Rasmussen, Miriam" uniqKey="Rasmussen M" first="Miriam" last="Rasmussen">Miriam Rasmussen</name><affiliation><mods:affiliation>Department of Immunology, Statens Seruminstitut, Artillerivej 5, DK-2300 Copenhagen S, Denmark</mods:affiliation></affiliation></author><author><name sortKey="Nielsen, Peter E" sort="Nielsen, Peter E" uniqKey="Nielsen P" first="Peter E." last="Nielsen">Peter E. Nielsen</name><affiliation><mods:affiliation>Department of Biochemistry B, Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark</mods:affiliation></affiliation></author><author><name sortKey="Manoharan, Muthia" sort="Manoharan, Muthia" uniqKey="Manoharan M" first="Muthia" last="Manoharan">Muthia Manoharan</name><affiliation><mods:affiliation>ISIS Pharmaceutical, 2280 Faraday Avenue. Carlsbad, CA 92008, USA</mods:affiliation></affiliation></author><author><name sortKey="Buchardt, Ole" sort="Buchardt, Ole" uniqKey="Buchardt O" first="Ole" last="Buchardt">Ole Buchardt</name><affiliation><mods:affiliation>Department of Organic Chemistry, H.C. Ørsted Institute, University of Copenhagen, Universitetsparken 5, DK-2100 Copenhagen Ø, Denmark</mods:affiliation></affiliation></author><author><name sortKey="Koch, Claus" sort="Koch, Claus" uniqKey="Koch C" first="Claus" last="Koch">Claus Koch</name><affiliation><mods:affiliation>Department of Immunology, Statens Seruminstitut, Artillerivej 5, DK-2300 Copenhagen S, Denmark</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Immunological Methods</title><title level="j" type="abbrev">JIM</title><idno type="ISSN">0022-1759</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996">1996</date><biblScope unit="volume">189</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="47">47</biblScope><biblScope unit="page" to="58">58</biblScope></imprint><idno type="ISSN">0022-1759</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1759</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acetic acid</term><term>Aluminum hydroxide suspension</term><term>Analog</term><term>Antibody response</term><term>Antiserum</term><term>Antiserum pools</term><term>Base sequence</term><term>Centrifugal evaporator</term><term>Conjugate</term><term>Detectable antibody response</term><term>Different conjugates</term><term>Hapten</term><term>Hplc</term><term>Inhibitory capacity</term><term>Microtiter plates</term><term>Midpoint</term><term>Midpoint position</term><term>Monothioate</term><term>Monothioate backbone</term><term>Nucleic</term><term>Nucleic acids</term><term>Oligonucleotide</term><term>Oligonucleotides</term><term>Reaction mixture</term><term>Sodium bicarbonate buffer</term><term>Strongest response</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The phosphoromonothioate oligonucleotide HPV (human papilloma virus) sequence (monothioate HPV) 5′-TTG, CTT,CCA,TCT,TCC,TCG,TC-3′ was photocoupled via three different sites (the 5′-end, the 3′-end and the midpoint) to PPD (purified protein derivative) and OA (ovalbumin), and the three types of conjugates (5′-HPV/carrier, 3′-HPV/carrier and midpoint-HPV/carrier) were used for the immunization of mice. Furthermore, a group of mice were immunized with the HPV sequence alone. No detectable antibody response against the monothioate HPV oligonucleotide was seen in mice receiving only the unconjugated monothioate HPV sequence. The OA-coupled monothioate HPV sequence also failed to elicit a detectable antibody response against the monothioate HPV oligonucleotide. However the PPD-conjugated monothioate HPV sequences induced a significant anti-monothioate HPV antibody response in BCG (bacille Calmette Guérin)-primed mice, a result that must be ascribed to the effect of using PPD as a carrier in BCG-primed mice. The antisera from all groups were tested on plates coated with the corresponding OA conjugates. By far the strongest response was obtained in mice receiving the HPV sequence coupled at the midpoint position. Further, all three groups of antisera obtained by immunizing with the different PPD conjugates were tested on microtiter plates coated with one of the three different OA conjugates. The antisera differed in their response depending on which OA conjugate was used for coating of the plate. Again, the midpoint-HPV/PPD antiserum showed the highest response, and this conjugate apparently represents the most efficient immunogen. Results from inhibition experiments with various relevant analogs of the monothioate HPV sequence showed that the three antiserum pools contained antibodies predominantly directed against the conformation of the monothioate backbone structure, but that at least a subpopulation of the antibodies recognized structures, which depended on the specific HPV base sequence.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>oligonucleotide</json:string><json:string>monothioate</json:string><json:string>oligonucleotides</json:string><json:string>hapten</json:string><json:string>hplc</json:string><json:string>analog</json:string><json:string>antiserum</json:string><json:string>base sequence</json:string><json:string>nucleic acids</json:string><json:string>nucleic</json:string><json:string>midpoint</json:string><json:string>inhibitory capacity</json:string><json:string>microtiter plates</json:string><json:string>conjugate</json:string><json:string>strongest response</json:string><json:string>reaction mixture</json:string><json:string>centrifugal evaporator</json:string><json:string>different conjugates</json:string><json:string>sodium bicarbonate buffer</json:string><json:string>aluminum hydroxide suspension</json:string><json:string>monothioate backbone</json:string><json:string>midpoint position</json:string><json:string>antibody response</json:string><json:string>detectable antibody response</json:string><json:string>antiserum pools</json:string><json:string>acetic acid</json:string></teeft></keywords><author><json:item><name>Miriam Rasmussen</name><affiliations><json:string>Department of Immunology, Statens Seruminstitut, Artillerivej 5, DK-2300 Copenhagen S, Denmark</json:string></affiliations></json:item><json:item><name>Peter E. Nielsen</name><affiliations><json:string>Department of Biochemistry B, Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark</json:string></affiliations></json:item><json:item><name>Muthia Manoharan</name><affiliations><json:string>ISIS Pharmaceutical, 2280 Faraday Avenue. Carlsbad, CA 92008, USA</json:string></affiliations></json:item><json:item><name>Ole Buchardt</name><affiliations><json:string>Department of Organic Chemistry, H.C. Ørsted Institute, University of Copenhagen, Universitetsparken 5, DK-2100 Copenhagen Ø, Denmark</json:string></affiliations></json:item><json:item><name>Claus Koch</name><affiliations><json:string>Department of Immunology, Statens Seruminstitut, Artillerivej 5, DK-2300 Copenhagen S, Denmark</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Antibody</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Phosphoromonothioate oligonucleotide antigen</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Carrier, Human papilloma virus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Virology</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>HPV : human papilloma virus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>PPD : purified protein derivative</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>BCG : bacille Calmette Guérin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>OA : ovalbumin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>diS : dithioate</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>monoS : phosphoromonothioate</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>SLE : systemic lupus erythematosus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dsDNA : double stranded DNA</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ssDNA : single stranded DNA</value></json:item></subject><arkIstex>ark:/67375/6H6-57Z5ZPTF-9</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: The phosphoromonothioate oligonucleotide HPV (human papilloma virus) sequence (monothioate HPV) 5′-TTG, CTT,CCA,TCT,TCC,TCG,TC-3′ was photocoupled via three different sites (the 5′-end, the 3′-end and the midpoint) to PPD (purified protein derivative) and OA (ovalbumin), and the three types of conjugates (5′-HPV/carrier, 3′-HPV/carrier and midpoint-HPV/carrier) were used for the immunization of mice. Furthermore, a group of mice were immunized with the HPV sequence alone. No detectable antibody response against the monothioate HPV oligonucleotide was seen in mice receiving only the unconjugated monothioate HPV sequence. The OA-coupled monothioate HPV sequence also failed to elicit a detectable antibody response against the monothioate HPV oligonucleotide. However the PPD-conjugated monothioate HPV sequences induced a significant anti-monothioate HPV antibody response in BCG (bacille Calmette Guérin)-primed mice, a result that must be ascribed to the effect of using PPD as a carrier in BCG-primed mice. The antisera from all groups were tested on plates coated with the corresponding OA conjugates. By far the strongest response was obtained in mice receiving the HPV sequence coupled at the midpoint position. Further, all three groups of antisera obtained by immunizing with the different PPD conjugates were tested on microtiter plates coated with one of the three different OA conjugates. The antisera differed in their response depending on which OA conjugate was used for coating of the plate. Again, the midpoint-HPV/PPD antiserum showed the highest response, and this conjugate apparently represents the most efficient immunogen. Results from inhibition experiments with various relevant analogs of the monothioate HPV sequence showed that the three antiserum pools contained antibodies predominantly directed against the conformation of the monothioate backbone structure, but that at least a subpopulation of the antibodies recognized structures, which depended on the specific HPV base sequence.</abstract><qualityIndicators><score>8.193</score><pdfWordCount>3193</pdfWordCount><pdfCharCount>24126</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>12</pdfPageCount><pdfPageSize>360 x 468 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>284</abstractWordCount><abstractCharCount>2030</abstractCharCount><keywordCount>13</keywordCount></qualityIndicators><title>Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence</title><pmid><json:string>8576579</json:string></pmid><pii><json:string>0022-1759(95)00227-8</json:string></pii><genre><json:string>research-article</json:string></genre><serie><title>Synthetic Peptides as Antigens</title><language><json:string>unknown</json:string></language><pages><first>25</first><last>57</last></pages></serie><host><title>Journal of Immunological Methods</title><language><json:string>unknown</json:string></language><publicationDate>1996</publicationDate><issn><json:string>0022-1759</json:string></issn><pii><json:string>S0022-1759(00)X0010-5</json:string></pii><volume>189</volume><issue>1</issue><pages><first>47</first><last>58</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1996</json:string></date><geogName></geogName><orgName><json:string>Biosystems</json:string><json:string>Danish National Research Foundation</json:string><json:string>Danish Natural Science Research Council</json:string></orgName><orgName_funder><json:string>Danish Natural Science Research Council</json:string></orgName_funder><orgName_provider></orgName_provider><persName><json:string>J. Med</json:string><json:string>R. Whelan</json:string></persName><placeName><json:string>Foster City</json:string><json:string>Germany</json:string><json:string>Palo Alto</json:string><json:string>Denmark</json:string><json:string>CA</json:string><json:string>Roskilde</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Lee et al.. 1987</json:string><json:string>MackworthYoung and Schwartz, 1988</json:string><json:string>Anderson et al., 1988</json:string><json:string>Lee et al., 1987</json:string><json:string>Gilkeson et al., 1989</json:string><json:string>Hasan and Ali, 1990</json:string><json:string>Cilkeson et al., 1989</json:string><json:string>Dawson and Bell, 1991</json:string><json:string>Plescia and Braun, 1967</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-57Z5ZPTF-9</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - immunology</json:string><json:string>2 - biochemical research methods</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - immunology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Immunology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1996</publicationDate><copyrightDate>1996</copyrightDate><doi><json:string>10.1016/0022-1759(95)00227-8</json:string></doi><id>0B7AD7322BCC0B8F6AAAD87B525D262EF65D4057</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-57Z5ZPTF-9/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-57Z5ZPTF-9/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-57Z5ZPTF-9/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1996</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note type="content">Section title: Research report</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence</title><author xml:id="author-0000"><persName><forename type="first">Miriam</forename><surname>Rasmussen</surname></persName><note type="correspondence"><p>Corresponding author. Tel.: + 45 32683595: Fax: +45 32683149.</p></note><affiliation>Department of Immunology, Statens Seruminstitut, Artillerivej 5, DK-2300 Copenhagen S, Denmark</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Peter E.</forename><surname>Nielsen</surname></persName><affiliation>Department of Biochemistry B, Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Muthia</forename><surname>Manoharan</surname></persName><affiliation>ISIS Pharmaceutical, 2280 Faraday Avenue. Carlsbad, CA 92008, USA</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Ole</forename><surname>Buchardt</surname></persName><affiliation>Department of Organic Chemistry, H.C. Ørsted Institute, University of Copenhagen, Universitetsparken 5, DK-2100 Copenhagen Ø, Denmark</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Claus</forename><surname>Koch</surname></persName><affiliation>Department of Immunology, Statens Seruminstitut, Artillerivej 5, DK-2300 Copenhagen S, Denmark</affiliation></author><idno type="istex">0B7AD7322BCC0B8F6AAAD87B525D262EF65D4057</idno><idno type="ark">ark:/67375/6H6-57Z5ZPTF-9</idno><idno type="DOI">10.1016/0022-1759(95)00227-8</idno><idno type="PII">0022-1759(95)00227-8</idno></analytic><monogr><title level="j">Journal of Immunological Methods</title><title level="j" type="abbrev">JIM</title><idno type="pISSN">0022-1759</idno><idno type="PII">S0022-1759(00)X0010-5</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996"></date><biblScope unit="volume">189</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="47">47</biblScope><biblScope unit="page" to="58">58</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1996</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: The phosphoromonothioate oligonucleotide HPV (human papilloma virus) sequence (monothioate HPV) 5′-TTG, CTT,CCA,TCT,TCC,TCG,TC-3′ was photocoupled via three different sites (the 5′-end, the 3′-end and the midpoint) to PPD (purified protein derivative) and OA (ovalbumin), and the three types of conjugates (5′-HPV/carrier, 3′-HPV/carrier and midpoint-HPV/carrier) were used for the immunization of mice. Furthermore, a group of mice were immunized with the HPV sequence alone. No detectable antibody response against the monothioate HPV oligonucleotide was seen in mice receiving only the unconjugated monothioate HPV sequence. The OA-coupled monothioate HPV sequence also failed to elicit a detectable antibody response against the monothioate HPV oligonucleotide. However the PPD-conjugated monothioate HPV sequences induced a significant anti-monothioate HPV antibody response in BCG (bacille Calmette Guérin)-primed mice, a result that must be ascribed to the effect of using PPD as a carrier in BCG-primed mice. The antisera from all groups were tested on plates coated with the corresponding OA conjugates. By far the strongest response was obtained in mice receiving the HPV sequence coupled at the midpoint position. Further, all three groups of antisera obtained by immunizing with the different PPD conjugates were tested on microtiter plates coated with one of the three different OA conjugates. The antisera differed in their response depending on which OA conjugate was used for coating of the plate. Again, the midpoint-HPV/PPD antiserum showed the highest response, and this conjugate apparently represents the most efficient immunogen. Results from inhibition experiments with various relevant analogs of the monothioate HPV sequence showed that the three antiserum pools contained antibodies predominantly directed against the conformation of the monothioate backbone structure, but that at least a subpopulation of the antibodies recognized structures, which depended on the specific HPV base sequence.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Antibody</term></item><item><term>Phosphoromonothioate oligonucleotide antigen</term></item><item><term>Carrier, Human papilloma virus</term></item><item><term>Virology</term></item></list></keywords></textClass><textClass><keywords scheme="keyword"><list><head>Abbreviations</head><item><term>HPV</term><term>human papilloma virus</term></item><item><term>PPD</term><term>purified protein derivative</term></item><item><term>BCG</term><term>bacille Calmette Guérin</term></item><item><term>OA</term><term>ovalbumin</term></item><item><term>diS</term><term>dithioate</term></item><item><term>monoS</term><term>phosphoromonothioate</term></item><item><term>SLE</term><term>systemic lupus erythematosus</term></item><item><term>dsDNA</term><term>double stranded DNA</term></item><item><term>ssDNA</term><term>single stranded DNA</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1995-07-24">Modified</change><change when="1996">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-57Z5ZPTF-9/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>JIM</jid><aid>95002278</aid><ce:pii>0022-1759(95)00227-8</ce:pii><ce:doi>10.1016/0022-1759(95)00227-8</ce:doi><ce:copyright type="unknown" year="1996"></ce:copyright></item-info><head><ce:dochead><ce:textfn>Research report</ce:textfn></ce:dochead><ce:title>Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence</ce:title><ce:author-group><ce:author><ce:given-name>Miriam</ce:given-name><ce:surname>Rasmussen</ce:surname><ce:cross-ref refid="COR1"><ce:sup>∗</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Peter E.</ce:given-name><ce:surname>Nielsen</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Muthia</ce:given-name><ce:surname>Manoharan</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>c</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Ole</ce:given-name><ce:surname>Buchardt</ce:surname><ce:cross-ref refid="AFF4"><ce:sup>d</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Claus</ce:given-name><ce:surname>Koch</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>a</ce:label><ce:textfn>Department of Immunology, Statens Seruminstitut, Artillerivej 5, DK-2300 Copenhagen S, Denmark</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>b</ce:label><ce:textfn>Department of Biochemistry B, Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>c</ce:label><ce:textfn>ISIS Pharmaceutical, 2280 Faraday Avenue. Carlsbad, CA 92008, USA</ce:textfn></ce:affiliation><ce:affiliation id="AFF4"><ce:label>d</ce:label><ce:textfn>Department of Organic Chemistry, H.C. Ørsted Institute, University of Copenhagen, Universitetsparken 5, DK-2100 Copenhagen Ø, Denmark</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Corresponding author. Tel.: + 45 32683595: Fax: +45 32683149.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="1" month="5" year="1995"></ce:date-received><ce:date-revised day="24" month="7" year="1995"></ce:date-revised><ce:date-accepted day="21" month="9" year="1995"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>The phosphoromonothioate oligonucleotide HPV (human papilloma virus) sequence (monothioate HPV) 5′-TTG, CTT,CCA,TCT,TCC,TCG,TC-3′ was photocoupled via three different sites (the 5′-end, the 3′-end and the midpoint) to PPD (purified protein derivative) and OA (ovalbumin), and the three types of conjugates (5′-HPV/carrier, 3′-HPV/carrier and midpoint-HPV/carrier) were used for the immunization of mice. Furthermore, a group of mice were immunized with the HPV sequence alone. No detectable antibody response against the monothioate HPV oligonucleotide was seen in mice receiving only the unconjugated monothioate HPV sequence. The OA-coupled monothioate HPV sequence also failed to elicit a detectable antibody response against the monothioate HPV oligonucleotide. However the PPD-conjugated monothioate HPV sequences induced a significant anti-monothioate HPV antibody response in BCG (bacille Calmette Guérin)-primed mice, a result that must be ascribed to the effect of using PPD as a carrier in BCG-primed mice. The antisera from all groups were tested on plates coated with the corresponding OA conjugates. By far the strongest response was obtained in mice receiving the HPV sequence coupled at the midpoint position. Further, all three groups of antisera obtained by immunizing with the different PPD conjugates were tested on microtiter plates coated with one of the three different OA conjugates. The antisera differed in their response depending on which OA conjugate was used for coating of the plate. Again, the midpoint-HPV/PPD antiserum showed the highest response, and this conjugate apparently represents the most efficient immunogen. Results from inhibition experiments with various relevant analogs of the monothioate HPV sequence showed that the three antiserum pools contained antibodies predominantly directed against the conformation of the monothioate backbone structure, but that at least a subpopulation of the antibodies recognized structures, which depended on the specific HPV base sequence.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Antibody</ce:text></ce:keyword><ce:keyword><ce:text>Phosphoromonothioate oligonucleotide antigen</ce:text></ce:keyword><ce:keyword><ce:text>Carrier, Human papilloma virus</ce:text></ce:keyword><ce:keyword><ce:text>Virology</ce:text></ce:keyword></ce:keywords><ce:keywords class="abr"><ce:section-title>Abbreviations</ce:section-title><ce:keyword><ce:text>HPV</ce:text><ce:keyword><ce:text>human papilloma virus</ce:text></ce:keyword></ce:keyword><ce:keyword><ce:text>PPD</ce:text><ce:keyword><ce:text>purified protein derivative</ce:text></ce:keyword></ce:keyword><ce:keyword><ce:text>BCG</ce:text><ce:keyword><ce:text>bacille Calmette Guérin</ce:text></ce:keyword></ce:keyword><ce:keyword><ce:text>OA</ce:text><ce:keyword><ce:text>ovalbumin</ce:text></ce:keyword></ce:keyword><ce:keyword><ce:text>diS</ce:text><ce:keyword><ce:text>dithioate</ce:text></ce:keyword></ce:keyword><ce:keyword><ce:text>monoS</ce:text><ce:keyword><ce:text>phosphoromonothioate</ce:text></ce:keyword></ce:keyword><ce:keyword><ce:text>SLE</ce:text><ce:keyword><ce:text>systemic lupus erythematosus</ce:text></ce:keyword></ce:keyword><ce:keyword><ce:text>dsDNA</ce:text><ce:keyword><ce:text>double stranded DNA</ce:text></ce:keyword></ce:keyword><ce:keyword><ce:text>ssDNA</ce:text><ce:keyword><ce:text>single stranded DNA</ce:text></ce:keyword></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence</title></titleInfo><name type="personal"><namePart type="given">Miriam</namePart><namePart type="family">Rasmussen</namePart><affiliation>Department of Immunology, Statens Seruminstitut, Artillerivej 5, DK-2300 Copenhagen S, Denmark</affiliation><description>Corresponding author. Tel.: + 45 32683595: Fax: +45 32683149.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Peter E.</namePart><namePart type="family">Nielsen</namePart><affiliation>Department of Biochemistry B, Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Muthia</namePart><namePart type="family">Manoharan</namePart><affiliation>ISIS Pharmaceutical, 2280 Faraday Avenue. Carlsbad, CA 92008, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ole</namePart><namePart type="family">Buchardt</namePart><affiliation>Department of Organic Chemistry, H.C. Ørsted Institute, University of Copenhagen, Universitetsparken 5, DK-2100 Copenhagen Ø, Denmark</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Claus</namePart><namePart type="family">Koch</namePart><affiliation>Department of Immunology, Statens Seruminstitut, Artillerivej 5, DK-2300 Copenhagen S, Denmark</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1996</dateIssued><dateModified encoding="w3cdtf">1995-07-24</dateModified><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: The phosphoromonothioate oligonucleotide HPV (human papilloma virus) sequence (monothioate HPV) 5′-TTG, CTT,CCA,TCT,TCC,TCG,TC-3′ was photocoupled via three different sites (the 5′-end, the 3′-end and the midpoint) to PPD (purified protein derivative) and OA (ovalbumin), and the three types of conjugates (5′-HPV/carrier, 3′-HPV/carrier and midpoint-HPV/carrier) were used for the immunization of mice. Furthermore, a group of mice were immunized with the HPV sequence alone. No detectable antibody response against the monothioate HPV oligonucleotide was seen in mice receiving only the unconjugated monothioate HPV sequence. The OA-coupled monothioate HPV sequence also failed to elicit a detectable antibody response against the monothioate HPV oligonucleotide. However the PPD-conjugated monothioate HPV sequences induced a significant anti-monothioate HPV antibody response in BCG (bacille Calmette Guérin)-primed mice, a result that must be ascribed to the effect of using PPD as a carrier in BCG-primed mice. The antisera from all groups were tested on plates coated with the corresponding OA conjugates. By far the strongest response was obtained in mice receiving the HPV sequence coupled at the midpoint position. Further, all three groups of antisera obtained by immunizing with the different PPD conjugates were tested on microtiter plates coated with one of the three different OA conjugates. The antisera differed in their response depending on which OA conjugate was used for coating of the plate. Again, the midpoint-HPV/PPD antiserum showed the highest response, and this conjugate apparently represents the most efficient immunogen. Results from inhibition experiments with various relevant analogs of the monothioate HPV sequence showed that the three antiserum pools contained antibodies predominantly directed against the conformation of the monothioate backbone structure, but that at least a subpopulation of the antibodies recognized structures, which depended on the specific HPV base sequence.</abstract><note type="content">Section title: Research report</note><subject><genre>Keywords</genre><topic>Antibody</topic><topic>Phosphoromonothioate oligonucleotide antigen</topic><topic>Carrier, Human papilloma virus</topic><topic>Virology</topic></subject><subject><genre>Abbreviations</genre><topic>HPV : human papilloma virus</topic><topic>PPD : purified protein derivative</topic><topic>BCG : bacille Calmette Guérin</topic><topic>OA : ovalbumin</topic><topic>diS : dithioate</topic><topic>monoS : phosphoromonothioate</topic><topic>SLE : systemic lupus erythematosus</topic><topic>dsDNA : double stranded DNA</topic><topic>ssDNA : single stranded DNA</topic></subject><relatedItem type="host"><titleInfo><title>Journal of Immunological Methods</title></titleInfo><titleInfo type="abbreviated"><title>JIM</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1996</dateIssued></originInfo><identifier type="ISSN">0022-1759</identifier><identifier type="PII">S0022-1759(00)X0010-5</identifier><part><date>1996</date><detail type="volume"><number>189</number><caption>vol.</caption></detail><detail type="issue"><number>1</number><caption>no.</caption></detail><extent unit="issue-pages"><start>1</start><end>144</end></extent><extent unit="pages"><start>47</start><end>58</end></extent></part></relatedItem><identifier type="istex">0B7AD7322BCC0B8F6AAAD87B525D262EF65D4057</identifier><identifier type="ark">ark:/67375/6H6-57Z5ZPTF-9</identifier><identifier type="DOI">10.1016/0022-1759(95)00227-8</identifier><identifier type="PII">0022-1759(95)00227-8</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-57Z5ZPTF-9/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001735 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001735 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:0B7AD7322BCC0B8F6AAAD87B525D262EF65D4057
|texte= Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence
}}
| This area was generated with Dilib version V0.6.33. |  |